肝素的测定。一种基于抗Xa因子增强作用的方法。 - Suppr

Suppr

超能文献

The measurement of heparin. A method based on the potentiation of anti-factor Xa.

作者信息

Denson K W, Bonnar J

出版信息

Thromb Diath Haemorrh. 1973 Dec 31;30(3):471-9.

PMID:4787668

Abstract

摘要

相似文献

The measurement of heparin. A method based on the potentiation of anti-factor Xa.肝素的测定。一种基于抗Xa因子增强作用的方法。

Thromb Diath Haemorrh. 1973 Dec 31;30(3):471-9.

The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.血小板、脑磷脂和组织因子对肝素抗凝活性的抑制作用。

Br J Haematol. 1984 Jun;57(2):229-38.

Thrombin generation and neutralization test (TGNT) - a simple, practical, and sensitive assay for plasma heparin quantitation.凝血酶生成与中和试验（TGNT）——一种用于血浆肝素定量的简单、实用且灵敏的检测方法。

Thromb Haemost. 1978 Jun 30;39(3):631-9.

Characterization of a new potent heparin. 2nd communication: Chemical analysis of the carbohydrate content and determination of the biological activity of a new potent heparin preparation in vitro, using protamine neutralization and amidolytic methods for factor Xa and thrombin.一种新型高效肝素的特性研究。第二篇通讯：采用鱼精蛋白中和法以及针对因子Xa和凝血酶的酰胺水解法，对新型高效肝素制剂的碳水化合物含量进行化学分析并测定其体外生物活性。

Arzneimittelforschung. 1980;30(7):1071-4.

Standard and method independent units for heparin anticoagulant activities.肝素抗凝活性的标准且与方法无关的单位。

Thromb Haemost. 1993 Nov 15;70(5):724-8.

In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.在心脏手术期间，对抑肽酶治疗患者监测抗凝水平时，肝素管理试验与活化凝血时间的体内和体外评估。

Heart Surg Forum. 2004;7(6):E599-604. doi: 10.1532/HSF98.20041134.

The characteristics of anticoagulation by covalently immobilized heparin.共价固定化肝素的抗凝特性。

J Biomed Mater Res. 1980 Sep;14(5):619-30. doi: 10.1002/jbm.820140508.

Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.体外循环期间高剂量肝素化监测——凝血酶原酶诱导凝血时间（PiCT）与两种发色底物法抗Xa因子活性测定的比较

Thromb Haemost. 2008 Feb;99(2):427-34. doi: 10.1160/TH07-04-0307.

Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.遗传性异常抗凝血酶III组分对凝血酶和因子Xa的抑制反应性。

Thromb Haemost. 1980 Oct 31;44(2):92-5.

[Action of vitreous body in the blood coagulation].[玻璃体在血液凝固中的作用]

Pathol Biol (Paris). 1969 Jan;17(1):31-7.

引用本文的文献

Mechanisms of Bioactivities of Fucoidan from the Brown Seaweed L. of the Barents Sea.巴伦支海褐藻 L. 中岩藻聚糖的生物活性机制。

Mar Drugs. 2020 May 22;18(5):275. doi: 10.3390/md18050275.

Physicochemical and Biological Characterization of Fucoidan from Fucus vesiculosus Purified by Dye Affinity Chromatography.通过染料亲和色谱法纯化的墨角藻岩藻聚糖的物理化学和生物学特性

Mar Drugs. 2016 Apr 15;14(4):79. doi: 10.3390/md14040079.

Sulfated Polysaccharides Isolated from Cloned Grateloupia filicina and Their Anticoagulant Activity.从克隆的蜈蚣藻中分离得到的硫酸化多糖及其抗凝活性。

Biomed Res Int. 2015;2015:612352. doi: 10.1155/2015/612352. Epub 2015 Apr 7.

Inhibition of intrinsic thrombin generation.抑制内源性凝血酶生成。

Drug Target Insights. 2006;1:5-10. Epub 2006 Oct 23.

An evaluation of the British Pharmacopoeial assay of heparin: a comparison with other methods.英国药典肝素测定法的评估：与其他方法的比较。

J Clin Pathol. 1980 Jun;33(6):562-5. doi: 10.1136/jcp.33.6.562.

Clinical pharmacokinetics of heparin.肝素的临床药代动力学

Clin Pharmacokinet. 1980 May-Jun;5(3):204-20. doi: 10.2165/00003088-198005030-00002.

Anticoagulants.抗凝剂。

Br Med J (Clin Res Ed). 1987 Feb 14;294(6569):428-30. doi: 10.1136/bmj.294.6569.428.

Heparin pharmacokinetics and pharmacodynamics.肝素的药代动力学和药效学。

Clin Pharmacokinet. 1992 May;22(5):359-74. doi: 10.2165/00003088-199222050-00003.

Editorial: Venous thromboembolism and anticoagulants in pregnancy.社论：妊娠期静脉血栓栓塞与抗凝剂

Br Med J. 1975 Nov 22;4(5994):421-2. doi: 10.1136/bmj.4.5994.421.

Letter: Adjustment to low-dose heparin to prevent thrombosis.信件：调整低剂量肝素以预防血栓形成。

Br Med J. 1975 Sep 20;3(5985):705. doi: 10.1136/bmj.3.5985.705.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验